UPDATE: Myriad's myPlan Lung Cancer Test Meets Primary Endpoint in Trial
September 25, 2013 at 07:02 AM EDT
SALT LAKE CITY, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN ) today announced new data published in Clinical Cancer Research that showed the myPlan Lung Cancer test is a significant predictor of lung cancer death in patients with early-stage, resectable lung adenocarcinoma and may be
